Antimicrobial susceptibilities of in Canada, 2021.

BACKGROUND

In Canada, gonorrhea is the second most prevalent bacterial sexually transmitted infection. The Gonococcal Antimicrobial Surveillance Programme (GASP - Canada), a passive surveillance system monitoring antimicrobial resistance in in Canada since 1985, is the source for this summary of demographics, antimicrobial resistance and multi-antigen sequence typing (NG-MAST) of gonococcal isolates collected in Canada in 2021.

METHODS

Provincial and territorial public health laboratories submitted cultures and data to the National Microbiology Laboratory in Winnipeg as part of the surveillance system. The antimicrobial resistance and molecular type of each isolate received were determined.

RESULTS

In total, 3,439 cultures were received from laboratories across Canada in 2021, a 9.9% increase since 2020 (n=3,130). Decreased susceptibility to cefixime increased significantly (<0.001) in 2021 (1.5%) compared to 2017 (0.6%). No significant change in decreased susceptibility to ceftriaxone was detected between 2017 and 2021 (0.6%) (>0.001); however, one ceftriaxone-resistant isolate was identified. Azithromycin resistance decreased significantly (<0.001) in 2021 (7.6%) compared to 2017 (11.7%); however, there was a significant increase (<0.001) in the proportion of cultures with an azithromycin minimum inhibitory concentration of at least 1 mg/L (2017=22.2% to 2021=28.1%). In 2021, NG-MAST-19875 (15.3%) was the most prevalent sequence type in Canada; 20.3% of isolates with this sequence type were resistant to azithromycin.

CONCLUSION

The spread of antimicrobial-resistant gonorrhea is a significant public health concern. The continued regional and national surveillance of antimicrobial resistance in is essential in ensuring effective treatment therapies are recommended.